TerminatedNot Applicable

Fetal Genome Profiling Via Trophoblast Cells

Stopped: Lack of personnel and funding resources

United States1 participantsStarted 2020-07-02

Plain-language summary

The objective of this study is to utilize trophoblast cells accumulating in the endocervical canal at the beginning of pregnancy for non-invasive prenatal testing. If we are able to validate that trophoblast cells obtained at an early gestational age can be reliably used for prenatal testing, there is great potential to improve early pregnancy management and counseling options for potential parents. The target population will be all women between the age of 18-45 undergoing care at the Center for Reproductive Medicine (CRM) in order to achieve a pregnancy.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women 18 to 45 who achieve a pregnancy during study time period. * If pregnancy result in miscarriage, cytogenetic testing must be completed on the product of conception. Exclusion Criteria: * Women whose cervical sample collection containing inadequate number of trophoblast cells for analysis.

What they're measuring

Occurrence of chromosomal anomalies as detected via fetal genome analysis of trophoblast cells

Timeframe: 6 weeks post pregnancy

Trial details

NCT IDNCT03832634

SponsorWeill Medical College of Cornell University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-14

View on ClinicalTrials.gov More Fetal Growth Retardation trials